![Peter Svalander](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Svalander
Corporate Officer/Principal en University of Gothenburg .
Cargos activos de Peter Svalander
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
University of Gothenburg | Corporate Officer/Principal | 02/06/2010 | - |
Historial de carrera de Peter Svalander
Antiguos cargos conocidos de Peter Svalander.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Swedish Biotechnology AB | Presidente | - | - |
Avaris AB
![]() Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Director/Miembro de la Junta | - | - |
Estadísticas
Internacional
Suecia | 4 |
Operativa
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
President | 1 |
Sectorial
Commercial Services | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Avaris AB
![]() Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Commercial Services |
Swedish Biotechnology AB |
- Bolsa de valores
- Insiders
- Peter Svalander
- Experiencia